Heron Therapeutics is trading 10.93% up at $0.36, rebounding as broader risk-on sentiment appears to support the move.
- Shares closed at $0.32 on August 11, 2026, after a sharp post-earnings decline.
- Second-quarter revenue missed estimates, and management withdrew full-year guidance amid CINVANTI patent uncertainty and a strategic-alternatives review.
- No new company-specific announcement clearly explains the August 12, 2026 gain; the Nasdaq advanced 0.67%.